Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
GNI Group ( (JP:2160) ) just unveiled an announcement.
GNI Group Ltd. announced an amendment to its Consolidated Financial Results for FY2024 due to a tax review of its subsidiary, GNI USA, Inc. The corrections involve adjustments to profit and loss figures, reflecting a minor improvement in profit attributable to owners of the parent and comprehensive income. These changes highlight the company’s ongoing financial adjustments and could impact stakeholder perceptions of its financial health.
More about GNI Group
GNI Group Ltd. operates in the biotechnology and pharmaceutical industry, focusing on developing and commercializing innovative therapies. The company is listed on the TSE Growth market and has a global presence with subsidiaries, including GNI USA, Inc.
Average Trading Volume: 42
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €1B
For a thorough assessment of 2160 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue